IOVANCE BIOTHERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Iovance Biotherapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q2 2024.
  • Iovance Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$97.1M, a 8.85% increase year-over-year.
  • Iovance Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$440M, a 5.11% decline year-over-year.
  • Iovance Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$444M, a 12.2% decline from 2022.
  • Iovance Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$396M, a 15.7% decline from 2021.
  • Iovance Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$342M, a 31.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$440M -$97.1M +$9.43M +8.85% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$450M -$113M -$5.61M -5.22% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$444M -$116M -$11.1M -10.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$433M -$114M -$14.1M -14.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$419M -$107M -$7.18M -7.23% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$412M -$107M -$15.8M -17.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$396M -$105M -$5.99M -6.03% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$390M -$99.6M -$13.5M -15.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$376M -$99.3M -$18M -22.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$358M -$91.6M -$16.2M -21.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$342M -$99.3M -$30.9M -45.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$311M -$86.1M -$27.6M -47% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$284M -$81.4M -$18.3M -29.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$265M -$75.4M -$5.85M -8.41% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$260M -$68.4M -$4.83M -7.6% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 -$255M -$58.6M -$9.08M -18.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$246M -$63M -$15.5M -32.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$230M -$69.6M -$32.6M -88.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$198M -$63.6M -$31M -95.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$167M -$49.5M -$15.7M -46.3% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$151M -$47.6M -$16.9M -55.1% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$134M -$37M -$10.4M -39.4% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$124M -$32.6M -$6.72M -26% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-25
Q3 2018 -$117M -$33.8M -$11.7M -52.7% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-25
Q2 2018 -$105M -$30.7M -$7.28M -31.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-25
Q1 2018 -$97.9M -$26.5M -$5.83M -28.2% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-25
Q4 2017 -$92.1M -$25.9M -$10.2M -64.8% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$81.9M -$22.1M +$46.1M +67.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$128M -$23.4M -$11.8M -102% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$116M -$20.7M -$13.8M -200% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$102M -$15.7M -$7.33M -87.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-12
Q3 2016 -$95M -$68.2M -$60.6M -793% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-12
Q2 2016 -$34.4M -$11.6M -$5.2M -81.6% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-12
Q1 2016 -$29.2M -$6.88M -$1.59M -29.9% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-12
Q4 2015 -$27.7M -$8.36M -$3.71M -79.7% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-09
Q3 2015 -$24M -$7.64M -$4.62M -153% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-09
Q2 2015 -$19.3M -$6.37M -$4.26M -202% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-09
Q1 2015 -$15.1M -$5.3M -$3.04M -134% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-09
Q4 2014 -$12M -$4.65M +$6.85M +59.5% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-11
Q3 2014 -$18.9M -$3.01M +$6.4M +68% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-11
Q2 2014 -$25.3M -$2.11M +$1.32M +38.5% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-11
Q1 2014 -$26.6M -$2.26M -$1.21M -116% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-11
Q4 2013 -$25.4M -$11.5M -$15M -432% Oct 1, 2013 Dec 31, 2013 10-K 2016-03-11
Q3 2013 -$10.4M -$9.41M -$8.74M -1296% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-13
Q2 2013 -$1.68M -$3.43M -$3.1M -948% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-08
Q1 2013 $1.42M -$1.05M +$4.73M +81.9% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-14
Q4 2012 -$3.31M $3.47M +$11.8M Oct 1, 2012 Dec 31, 2012 10-K 2014-03-28
Q3 2012 -$15.1M -$674K +$5.14M +88.4% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-14
Q2 2012 -$20.3M -$327K +$10.6M +97% Apr 1, 2012 Jun 30, 2012 10-Q 2013-10-23
Q1 2012 -$30.9M -$5.77M -$5.21M -923% Jan 1, 2012 Mar 31, 2012 10-Q 2013-10-23
Q4 2011 -$25.7M -$8.35M Oct 1, 2011 Dec 31, 2011 10-K 2014-03-28
Q3 2011 -$5.82M -$5.1M -715% Jul 1, 2011 Sep 30, 2011 10-Q 2013-01-25
Q2 2011 -$11M -$10.9M -12850% Apr 1, 2011 Jun 30, 2011 10-Q/A 2012-09-10
Q1 2011 -$564K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-15
Q3 2010 -$714K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-21
Q2 2010 -$84.6K Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-09-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.